Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial
Muhammad Shipa(The Royal Free Hospital), Michael R. Ehrenstein, Andrew Embleton-Thirsk(University of Waterloo), Caroline Gordon(University of Birmingham), David Isenberg(Regenerative Medicine Institute), Mariea Parvaz(The Royal Free Hospital), Dao X. Nguyen(The Royal Free Hospital), Lauren L Heptinstall(The Royal Free Hospital), Ruth J. Pepper(University College Hospital), Liliana Ribeiro Santos(The Royal Free Hospital)
Cited by 40
Related Papers
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
|Annals of the Rheumatic Diseases|2013|454
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial
|The Lancet Haematology|2016|404
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease
|Lara D. Veeken|2003|367
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
|Annals of the Rheumatic Diseases|2016|355